CytoSorbents 2025 revenue rises, net loss narrows

Cytosorbents

25/03/2026 20:25

Overview

U.S. blood purification device maker's 2025 revenue grew 4%, flat on constant currency

Company implemented workforce and cost reduction program in Q4

Secured $2.5 mln additional liquidity through amended credit facility in November

Outlook

CytoSorbents expects to achieve cash flow breakeven in the second half of 2026

CytoSorbents expects incremental improvement in commercial activity across 2026

Result Drivers

GERMAN SALES DECLINE - Co said 10% drop in Germany annual sales reflected restructuring of sales operations and new strategies

COST REDUCTION - Co implemented workforce and cost reduction program in Q4 to lower expenses and accelerate cash flow breakeven

Company press release: ID:nPnc7zYJHa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$0.13


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cytosorbents Corp is $5.00, about 618.6% above its March 24 closing price of $0.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)